Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

Management to Make Two Presentations on the Topic of Drug Repurposing and

Indian Clinical Trial Strategy

MORRISTOWN, N.J., Aug. 16 /PRNewswire/ -- Vicus Therapeutics, Inc., an oncology-focused, clinical-stage biopharmaceutical company, announced today that Chief Executive Officer, John Maki, and Chief Scientific Officer, Frederic Young, Ph.D., will each present at the 234th American Chemical Society National Meeting on Sunday, August 19, 2007. The Meeting is being held at the Boston Convention & Exhibition Center in Boston, MA.

Dr. Young will present "Hypothesis-driven Drug Repurposing Based on a Novel Systems Biology Approach," including a discussion of Vicus' complexity theory-based drug repurposing approach in creating a pipeline of product candidates for the treatment of important unmet medical needs. The Company's approach can be applied to the discovery of product candidates for any indication, including cancer cachexia, a metabolic disorder, mucositis, a wound healing disorder, and cancer fatigue, a CNS disorder. The specific application of this method will be discussed in the context of the Company's lead compound, VT-122. Dr. Young's presentation is scheduled for 11:45 a.m.

Mr. Maki's presentation, entitled "Synergistic Advantages of Drug Repurposing and Clinical Trial Off-shoring in India", will include a discussion of the unique synergistic advantages of drug re-profiling and off- shoring, as well as an overview of the steps necessary to realize such advantages. Specifically, Mr. Maki will provide highlights from the Company's ongoing Phase 2 clinical trial of VT-122 for cancer cachexia, now being conducted in the U.S. and India. In addition, he will review recent changes by the Drug Controller General of India (DCGI, the Indian FDA-regulatory equivalent), Indian clinical research infrastructure, and the acceptance of Indian data by the U.S. Food & Drug Administration (FDA) that is currently driving the expl
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) has announced the addition ... Testing services - Global Forecast to 2020" report ... market is estimated to be worth around $2.5 billion ... during the forecast period of 2014 to 2020 ... protein consumption, increasing adoption of advanced genetic technologies for ...
(Date:5/28/2015)... -- Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... institutional healthcare investors to purchase an aggregate of approximately ... at-the-market registered direct offering and a concurrent private placement ... Company entered into a definitive purchase agreement with these ... an aggregate of 3,000,000 shares of its common stock ...
(Date:5/28/2015)... May 28, 2015  PDS Biotechnology Corp. announces ... treatment targeting HPV-16, has generated strong T-cell responses ... pre-cervical cancer is treated by surgical removal of ... effective non-surgical alternative. Results show that it primes ... recognize, target, and kill precancerous and cancerous cells ...
(Date:5/28/2015)... New York and London (PRWEB) May 28, 2015 ... CFD-focused provider of Computer Aided Engineering software, announced ... Solid Research, Inc. (PSRI). CD-adapco will provide state-of-the-art ... PSRI members will share their expertise and experiences ... chemical and refining industry members and advance the ...
Breaking Biology Technology:Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... Auxogyn, Inc., a privately held medical technology company ... acquired an exclusive license from Stanford University to develop ... in the field of assisted reproduction to significantly improve ... procedures. The technology licensed from Stanford is ...
... Calif., Oct. 4 Dainippon Sumitomo Pharma Co., Ltd. ... have entered into an option agreement to co-develop a ... the agreement, DSP has received an option for exclusive ... a promising cell therapy drug candidate being developed by ...
... BOTHELL, WA and VANCOUVER, Oct. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... of OncoGenex will present at the 9th Annual BIO Investor ... The Palace Hotel in San Francisco, CA. Live ... Relations page of the OncoGenex Web site at http://ir.oncogenex.com ...
Cached Biology Technology:Auxogyn Licenses Non-invasive Embryo Assessment Technology From Stanford University 2Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery 2OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum 2
(Date:5/21/2015)... 21, 2015 The Sync Project™ , ... for health, today announced a collaborative partnership with ... will center on collaboration on original research, joint course ... in the collaboration, The Sync Project and BerkleeICE are ... Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/11/2015)... a well-rounded UAS delegation representing private industry, government, and academia, ... AUVSI,s Unmanned 2015 conference last week in Atlanta ... UAS industry met with over 200 hundred people from companies ... ecosystem. "Our message is clear and consistent," ... Rich Knoll . "If you want to fly UAS, you ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... de dezembro de  2012 A Integrated Biometrics, ... a certificação pelo FBI de sua novíssima tecnologia ... IB criou o novo produto usando a tecnologia ... com um transistor de película fina (TFT). A ...
... methodologies of identifying genes that contribute to the ... in several immune-system-related pathways contribute to development of ... 4 in the open-access journal PLOS ONE ... function in autism by integrating analysis of autism-associated ...
... and Cargill have renewed their partnership to eliminate lymphatic filariasis ... disease that affects over 2 million Haitians and is the ... is truly a national disease in Haiti and 87 percent ... of coastal Haiti, as much as half of the population ...
Cached Biology News:Integrated Biometrics Apresenta Sherlock, o Menor, Mais Leve e Fino Sensor Appendix F Mobile ID 2Combining two genome analysis approaches supports immune system contribution to autism 2Combining two genome analysis approaches supports immune system contribution to autism 3Cargill expands support of Notre Dame Haiti Program 2Cargill expands support of Notre Dame Haiti Program 3
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA ...
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Agarose Gel Loading Dye Mixture 6X...
Biology Products: